Ontology highlight
ABSTRACT: Background
This study investigated the characteristics of prostate-specific antigen (PSA) dynamics when androgen receptor signaling inhibitor (ARSI), or vintage agent (bicalutamide) was used for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Patients and methods
A total of 213 mHSPC patients from each of the ARSI and bicalutamide groups treated between 2015 and 2022 were selected from multiple institutions using propensity score-matched analysis to align backgrounds. PSA progression-free survival (PFS) and overall survival (OS) were assessed. PSA level at 3 months, PSA nadir level, and time to PSA nadir were examined to analyze of PSA kinetics.Results
ARSI treatment significantly improved PSA PFS compared to bicalutamide (P = 0.0063), although no
SUBMITTER: Yamada Y
PROVIDER: S-EPMC11842405 | biostudies-literature | 2025 Mar
REPOSITORIES: biostudies-literature